Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News in Healthcare

Articles with a lock require a GLG News subscription.
October 20, 2008
Stent Oligopoly: bigger stakes, bigger trials.
Analysis of: Health Firms to Study Clots in Stent Patients | online.wsj.com
Author: GLG Expert Contributor
This collaboration will be very successful: the trial involving 20 000 patients will take a long time to complete. During the trial utilization of stents will not change. Upon completion of the trial it will become even more obvious that 2 years of "blood thinning" is better than 1 year for stents potency rates. The complications of prolonged "blood thinning", however, will promote search for...
October 20, 2008
Amiodarone is here to stay.
Analysis of: Wyeth Heart Drug Not A Short-Term Option | www.pharmalot.com
Author: GLG Expert Contributor
Amiodarone is still one of the best drugs for atrial fibrillation despite "rare incidence" of cirrhosis, lung fibrosis and now "rare muscle injury".
October 20, 2008
Medtronic: chasing the tail.
Analysis of: Medtronic Endeavor Heart Stent Tied to Complications | www.bloomberg.com
Author: GLG Expert Contributor
Utilization of a device in a setting of marginal data is not driven by that data, but by the reimbursement rates. Medtronc might loose the battle, but stents are still winning the war.
Donald FlemingOctober 20, 2008
We must hit the cancer target by genetics or whatever technique
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Targeted therapy for cancer is the new trend Targeted therapy will allow the use of more expensive drugs to be more practical We need to focus on hitting a target more than ever
Donald FlemingOctober 20, 2008
Government Run Cancer care
Analysis of: Roche Cuts Price of Cancer Drug | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
There has been distubing trends in nationalized health care in regrds to cancer care Recently the UK made an absolutely shocking decision on renal cancer therapy, as it has in other cancers in the past Hopefully through advances in predicting cancer therapy outcomes via microarray etc. we can keep progressing as we have over the past decade with targeted therapy
October 20, 2008
Successful Collaboration Is Better Than Individual Failure
Analysis of: Health Firms to Study Clots in Stent Patients | online.wsj.com
Author: GLG Expert Contributor
This plan to start a large trial to determine the optimal antiplatelet therapy. after [drug-eluting] stent implantation makes sense both scientifically and economically for the involved stent companies (Johnson & Johnson, Boston Scientific, Medtronic and Abbott). Sanofi-Aventis and Bristol Myers Squibb, who market clopidogrel (Plavix) are likely also interested to have more precise data out...
October 20, 2008
Despite Bailout, Feds Still Have Cash Left for Physicians to Implement Electronic Records
Analysis of: Small Practices to get Financial Boost with new Health IT Incentive Program | www.healthimaging.com
Author: GLG Expert Contributor
Even after the trillion dollars which the federal government has had to spend to prop up the nation's financial system during the past month, it still has some real money left to subsidize the costs of physicians in smaller practices willing to implement electronic records.  With electronic records as a necessary ingredient in any healthcare reform package next year regardless of who occupies...
October 17, 2008
The Hazards of Herbal Self-Medication
Analysis of: St John's Wort 'as good as Prozac' | ukpress.google.com
Author: GLG Expert Contributor
St. John's Wort has long been promoted as "herbal Prozac", claiming the added benefits of being natural and affordable. If fact, reading the proponents' comments, one would think St. John's Wort is health food.   The concentration of hypericin, the key pharmacologically active constituent in commercial St. John's Wort preparaations, is highly variable. One study known to this author...
October 17, 2008
Everyone wins when patients get drugs they are most likely to offer a benefit
Analysis of: Genetic Research May Help Pick Patients' Best Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Being able to select the right drug for the righ patient benefits everyone, most importantly patients, but also the drug company.  Developing drugs specifically for a small, but targeted population likley means you get a much higher level of efficacy for a smaller population making the risk-benefit ratio of the drug much better.  Ultimately, this benefits pharma/biotech companies by having...
Michael WolffOctober 17, 2008
Oxybutinin gel will fill a niche in OAB treatment
Analysis of: Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference | www.pipelinereview.com
Author: Michael Wolff, Urologist, Alamance Regional Medical Center, Inc
Ditropan XL and generic ditropan have significant side effects and oxytrol patches can cause skin irritation. These problems may be avoided with oxybutinin gel.
Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next101 to 110 of 5529

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-11-20T05:45:44.710